| [1] |
Gamboa AC, Gronchi A, Cardona K. Soft-tissue sarcoma in adults: an update on the current state of histiotype-specific management in an era of personalized medicine[J]. CA Cancer J Clin, 2020, 70(3):200-229.
doi: 10.3322/caac.21605
URL
|
| [2] |
Lewis JJ, Leung D, Woodruff JM, et al. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution[J]. Ann Surg, 1998, 228(3):355-365.
doi: 10.1097/00000658-199809000-00008
pmid: 9742918
|
| [3] |
Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients[J]. J Clin Oncol, 2009, 27(1):24-30.
doi: 10.1200/JCO.2008.17.8871
pmid: 19047283
|
| [4] |
Bonvalot S, Rivoire M, Castaing M, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control[J]. J Clin Oncol, 2009, 27(1):31-37.
doi: 10.1200/JCO.2008.18.0802
pmid: 19047280
|
| [5] |
Milne I. Who was James Lind, and what exactly did he achieve[J]. J R Soc Med, 2012, 105(12):503-508.
doi: 10.1258/jrsm.2012.12k090
URL
|
| [6] |
Raistrick H, Scadding JG, Tytler WH, et al. Streptomycin treatment of pulmonary tuberculosis[J]. Br Med J, 1948, 2(4582):769-782.
|
| [7] |
Ergina PL, Cook JA, Blazeby JM, et al. Challenges in evaluating surgical innovation[J]. Lancet, 2009, 374(9695):1097-1104.
doi: 10.1016/S0140-6736(09)61086-2
pmid: 19782875
|
| [8] |
Barkun JS, Aronson JK, Feldman LS, et al. Evaluation and stages of surgical innovations[J]. Lancet, 2009, 374(9695):1089-1096.
doi: 10.1016/S0140-6736(09)61083-7
pmid: 19782874
|
| [9] |
The Lancet. Surgical research: the reality and the IDEAL[J]. Lancet, 2009, 374(9695):1037.
doi: 10.1016/S0140-6736(09)61678-0
pmid: 19782850
|
| [10] |
Strauss DC. Patterns of recurrence in retroperitoneal liposarcomas: reflecting surgical approach or tumor biology?[J]. Ann Surg Oncol, 2014, 21(7):2113-2116.
doi: 10.1245/s10434-014-3644-3
pmid: 24647676
|
| [11] |
Hartgritik HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? final results of the randomized Dutch Gastric Cancer group trial[J]. J Clin Oncol, 2004, 22(11):2069-2077.
doi: 10.1200/JCO.2004.08.026
pmid: 15082726
|
| [12] |
Songun I, Putter H, Kranenbarg EMK, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J]. Lancet Oncol, 2010, 11(5):439-449.
doi: 10.1016/S1470-2045(10)70070-X
pmid: 20409751
|
| [13] |
Tseng WW, Tsao-Wei DD, Callegaro D, et al. Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma[J]. Eur J Surg Oncol, 2018, 44(6):810-815.
doi: S0748-7983(18)30123-9
pmid: 29452860
|
| [14] |
Wang Z, Wu J, Lv A, et al. Infiltration characteristics and influencing factors of retroperitoneal liposarcoma: novel evidence for extended surgery and a tumor grading system[J]. Biosci Trends, 2018, 12(2):185-192.
doi: 10.5582/bst.2018.01015
pmid: 29657244
|
| [15] |
Bonvalot S, Gronchi A, Le Péchoux C, et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2020, 21(10):1366-1377.
doi: S1470-2045(20)30446-0
pmid: 32941794
|
| [16] |
van Houdt WJ, Raut CP, Bonvalot S, et al. New research strategies in retroperitoneal sarcoma. The case of TARPSWG, STRASS and RESAR: making progress through collaboration[J]. Curr Opin Oncol, 2019, 31(4):310-316.
doi: 10.1097/CCO.0000000000000535
pmid: 30893150
|
| [17] |
Dickson MA, Tap WD, Keohan ML, et al. Phase Ⅱ trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma[J]. J Clin Oncol, 2013, 31(16):2024-2028.
doi: 10.1200/JCO.2012.46.5476
pmid: 23569312
|
| [18] |
Bill KL, Garnett J, Meaux I, et al. SAR405838: a novel and potent inhibitor of the MDM2:p53 axis for the treatment of dedifferentiated liposarcoma[J]. Clin Cancer Res, 2016, 22(5):1150-1160.
doi: 10.1158/1078-0432.CCR-15-1522
pmid: 26475335
|
| [19] |
Gounder MM, Razak AA, Somaiah N, et al. Selinexor in advanced, metastatic dedifferentiated liposarcoma: a multinational, randomized, double-blind, placebo-controlled trial[J]. J Clin Oncol, 2022, 40(22):2479-2490.
doi: 10.1200/JCO.21.01829
URL
|
)
